• Contact Us

  • Pipeline
    NM002 (Nylexa®) for COVID 19 NM002 (Nylexa®) for AMR NM001 (Lynovex®) NP339 for Invasive Fungal Disease NP339 for Respiratory Fungal Disease NP213 (Novexatin®)) NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • Therapeutic Focus
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Technology
  • Pipeline
    • NM002 (Nylexa®) for COVID19
    • NM002 (Nylexa®) for AMR
    • NM001 (Lynovex®)
    • NP339 for Invasive Fungal Disease
    • NP339 for Respiratory Fungal Disease
    • NP213 (Novexatin®)
    • NP432
  • Contact Us

NovaBiotics Welcomes the UK Governments Announcement on Tackling Antimicrobial Resistance (AMR)

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 UK 20 Year Vision for Antimicrobial Resistance Deborah O’Neil, NovaBiotics CEO commented on today’s announcement: “AMR continues to pose a massive global health and socio-economic threat of a scale that cannot be underestimated or ignored....

Recent Posts

  • Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
  • NovaBiotics Attending BIO CEO & Investor Digital Conference
  • Just when we thought things were getting better…..
  • CARE CF 1 oral Lynovex clinical trial data published
  • NovaBiotics in the press

Recent Comments

    NovaBiotics Ltd
    Silverburn Crescent
    Bridge of Don
    Aberdeen
    AB23 8EW, UK

    Tel:+44 (0)1224 711377

    Registered Company
    No. SC272344

    NovaBiotics Inc
    One Boston Place,
    Suite 2600,
    Boston
    MA, 02108

    Tel:+1 866 259 4527

    NovaBiotics
    90 Upper George's Street,
    Dun Laoghaire,
    Co. Dublin,
    A96 R8R9

    Tel:+353 1 2712605

    Registered Company
    No. 642058

    News and Events

    About Us

    Therapeutic Focus

    Technology

    Pipeline

    Contact Us